Dr. Simos Kedikoglou Named President, COO at Anumana

Anumana has welcomed a new member to its executive management ranks, appointing Dr. Simos Kedikoglou as president and chief operating officer (COO).

Dr. Kedikoglou has a distinguished track record in global healthcare strategy, medical device commercialization, and operational leadership. In his new role, he will lead Anumana’s commercial operations, drive strategic partnerships, and oversee the development and execution of growth initiatives to advance the company’s mission to transform healthcare through artificial intelligence (AI) technology.

“Simos is a visionary leader with a deep understanding of the healthcare ecosystem and a proven track record of driving growth and innovation in the medtech space,” Anumana CEO Maulik Nanavaty said. “We are excited to welcome Simos to our team as we expand our impact in the healthcare industry. His extensive experience in medical device development and commercialization will help Anumana achieve its vision to deliver groundbreaking AI-powered solutions to improve patient outcomes.”

Dr. Kedikoglou most recently served as CEO of Impulse Dynamics, where he led the global commercialization of the Optimizer, the first active implantable device for heart failure treatment. During his tenure, Simos secured $350 million in funding and advanced multiple clinical trials, enrolling more than 5,000 patients. During the COVID-19 pandemic, he helped the company reach a $40 million revenue run rate and expanded its commercial team to more than 150 members.

He also played key roles as an executive board member at MedAlliance, helping raise $150 million and facilitate its sale to Cordis. Previously, he was the corporate vice president of Business Development at Boston Scientific, managing global deals and acquisitions, and as an associate partner at McKinsey & Company, advising on $45 billion in healthcare transactions.

“Anumana is at the forefront of an exciting transformation in healthcare, and it is an honor to join this team,” Dr. Kedikoglou stated. “The opportunity to harness AI’s potential to transform cardiovascular care is inspiring and the potential is unlimited. I am eager to apply my experience in scaling medical technologies to help Anumana achieve its bold vision of improving patient outcomes and advancing healthcare globally.”

Dr. Kedikoglou earned a medical degree from the University of Athens, Greece, an MBA with distinction from Harvard Business School, a master’s degree in public health from Harvard University, and is a CFA charterholder.

Anumana is an AI-driven health technology company leveraging cutting-edge AI and translational science to unlock the heart’s electrical language. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI solutions aim to detect diseases earlier using standard-of-care ECG readings. Its 12-lead algorithm, ECG-AI LEF, is now available in the United States.